Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Summary

RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast.

Timeline

Start

2002-10

Primary completion

2004-07

Completion

2005-06

Outcome

Outcome not reported

Stopped: “PI left VICC”

Drugs

Indications